Aura Biosciences, Inc. AURA
Institutional shares held
39.9 Million
400
calls
1.5K
puts
Total value of holdings
$290M
$2K
calls
$10K
puts
Market Cap
$213M
29,273,600
Shares Out.
Institutional ownership
136.13%
# of Institutions
78
We take great care to ensure that the data presented and summarized in this overview for Aura Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURA
View all-
Matrix Capital Management Company, LP Waltham, MA6.92MShares$50.3 Million0.5% of portfolio
-
Eventide Asset Management, LLC Boston, MA5.8MShares$42.2 Million0.73% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.47MShares$32.5 Million0.07% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.68MShares$26.7 Million0.01% of portfolio
-
Medicxi Ventures Management (Jersey) LTD3.04MShares$22.1 Million6.26% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$17.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.69MShares$12.3 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.45MShares$10.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.32MShares$9.61 Million0.67% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC1.16MShares$8.46 Million5.77% of portfolio
Latest Institutional Activity in AURA
Top Purchases
Top Sells
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2024
|
Conor Kilroy General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+50.0%
|
-
|
|
Feb 01
2024
|
Pinos Elisabet De Los |
BUY
Grant, award, or other acquisition
|
Direct |
162,935
+33.44%
|
-
|
|
Feb 01
2024
|
Julie B Feder Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
71,285
+34.68%
|
-
|
|
Feb 01
2024
|
Janet Jill Hopkins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,515
+14.85%
|
-
|
|
Jan 23
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
15,853
-8.94%
|
$110,971
$7.64 P/Share
|
|
Jan 23
2024
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,609
-9.5%
|
$46,263
$7.64 P/Share
|
|
Nov 09
2023
|
Matrix Capital Management Company, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,560,000
+18.39%
|
$14,040,000
$9.0 P/Share
|
|
Nov 08
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Indirect |
20,000
+11.76%
|
$140,000
$7.3 P/Share
|
|
Nov 08
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Direct |
9,601
+6.61%
|
$67,207
$7.3 P/Share
|
|
Nov 07
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Indirect |
94,000
+41.96%
|
$658,000
$7.17 P/Share
|
|
Nov 07
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Direct |
76,000
+37.61%
|
$532,000
$7.17 P/Share
|
|
Nov 06
2023
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
7,449
-4.03%
|
$89,388
$12.03 P/Share
|
|
Nov 06
2023
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+2.02%
|
$7,600
$2.74 P/Share
|
|
Nov 06
2023
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,900
-5.31%
|
$46,800
$12.07 P/Share
|
|
Nov 06
2023
|
Julie B Feder Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,900
+5.04%
|
$7,800
$2.74 P/Share
|
|
Nov 01
2023
|
Janet Jill Hopkins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+50.0%
|
-
|
|
Oct 30
2023
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
9,586
-5.03%
|
$57,516
$6.83 P/Share
|
|
Oct 30
2023
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,385
-4.64%
|
$20,310
$6.82 P/Share
|
|
Oct 04
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Direct |
6,566
+11.59%
|
$52,528
$8.61 P/Share
|
|
Oct 03
2023
|
David Michael Johnson |
BUY
Open market or private purchase
|
Direct |
13,500
+23.68%
|
$108,000
$8.27 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.28M
Shares
From
8
Insiders
| Open market or private purchase | 1.78M shares |
|---|---|
| Grant, award, or other acquisition | 494K shares |
| Exercise of conversion of derivative security | 7.7K shares |
Sell / Disposition
46.8K
Shares
From
2
Insiders
| Open market or private sale | 46.8K shares |
|---|